Does Group Health Cooperative (GHC) Cover Forteo?

What Is Forteo and Why Does It Require Special Approval?

Forteo (teriparatide) is a recombinant fragment of human parathyroid hormone used to build new bone in patients with severe osteoporosis. Unlike bisphosphonates, which slow bone loss, teriparatide is an anabolic agent that stimulates osteoblast activity. Because of its high cost, injectable delivery, and a boxed warning about osteosarcoma risk observed in animal studies, every major U.S. insurer, including GHC-affiliated plans, places it under prior authorization (PA) with step-therapy requirements.

The FDA approved teriparatide in November 2002 for postmenopausal women and men at high fracture risk, and the label limits lifetime use to 24 months. That 24-month cap is itself one reason insurers scrutinize the drug closely: approving it commits the plan to a predictable, finite but expensive course of therapy. The FDA prescribing information states that "the safety and efficacy of teriparatide have not been evaluated beyond 2 years of treatment." Most GHC PA criteria mirror that language directly.

Osteoporosis is widespread. The CDC estimates that approximately 10 million Americans over age 50 have osteoporosis, and another 44 million have low bone density, placing them at elevated fracture risk. Bisphosphonates such as alendronate (Fosamax) and risedronate (Actonel) are inexpensive, generic, and covered on Tier 1 or Tier 2 by virtually every formulary, which is why insurers require documented failure of those agents before approving a drug that costs 30 to 50 times more per year.

How GHC Formularies Are Structured

Group Health Cooperative operates as a cooperative health plan model, primarily serving Washington State and Idaho. Its pharmacy benefits are administered through its own formulary committees, and plans sold through employer groups, the individual market, and Medicare Advantage each carry slightly different formulary tiers and PA criteria.

GHC commercial plans typically use a four- to five-tier structure:

• Tier 1: Low-cost generics (most bisphosphonates)
• Tier 2: Preferred brand-name and higher-cost generics
• Tier 3: Non-preferred brands
• Tier 4/Specialty: High-cost injectables and biologics, including Forteo

Specialty-tier drugs almost always require PA. For Medicare Advantage members, the Part D formulary rules apply, and CMS requires that PA criteria be clinically based and not arbitrary. The CMS Medicare Prescription Drug Benefit Manual, Chapter 6 specifies that utilization management criteria must be "based on current evidence in widely used treatment guidelines."

Because GHC periodically updates its formulary, the most accurate coverage information at any given moment comes from the GHC online drug search tool or by calling GHC member services directly. Formularies can change on January 1 of each plan year, and mid-year changes are also possible for drugs that receive new FDA labeling.

Typical Prior Authorization Criteria for Forteo on GHC Plans

GHC's PA requirements for teriparatide typically align with the clinical criteria published by the American Association of Clinical Endocrinology (AACE) and the Endocrine Society. Based on standard industry PA templates and GHC's published formulary policies, an approvable PA submission generally requires all of the following elements:

1. Confirmed diagnosis of osteoporosis. A dual-energy X-ray absorptiometry (DXA) scan showing a T-score of -2.5 or lower at the spine, total hip, or femoral neck, or documented fragility fracture (vertebral or hip) even at a higher T-score.

2. High fracture risk designation. Tools such as FRAX (Fracture Risk Assessment Tool) can support this. A 10-year major osteoporotic fracture probability above 20%, or hip fracture probability above 3%, meets the National Osteoporosis Foundation threshold cited in many PA templates.

3. Step-therapy documentation. The prescribing physician must show that the patient tried and failed, or has a documented clinical contraindication to, at least one oral bisphosphonate. "Failure" typically means persistent bone density decline or new fracture while adherent to therapy for 12 months or more. Contraindications include severe renal impairment (CrCl <35 mL/min), esophageal disorders, or documented intolerance (esophagitis, severe GI events).

4. Prescriber specialty. Some GHC plan versions require that Forteo be prescribed by or in consultation with an endocrinologist, rheumatologist, or specialist in metabolic bone disease.

5. Absence of contraindications to teriparatide. Hypercalcemia, prior radiation therapy to the skeleton, Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, and prior osteosarcoma are all FDA-labeled contraindications that would make the PA approvable on clinical grounds alone but would prevent appropriate prescribing.

The 2020 AACE/ACE Clinical Practice Guideline states: "Anabolic therapy should be considered as initial therapy for very high-risk patients, defined as those with recent fracture, very low T-score (below -3.0), or who have failed antiresorptive therapy." This guideline language is often quoted directly in PA appeal letters to justify skipping bisphosphonate step therapy in very high-risk patients.

What Teriparatide Costs Without and With GHC Coverage

Without insurance, Forteo's wholesale acquisition cost runs approximately $3,000 to $3,500 per 28-day pen in 2024. A full 24-month course therefore carries a list-price total of roughly $72,000 to $84,000 before any discounts, a figure that explains insurer scrutiny.

Generic teriparatide (the first biosimilar-equivalent, Bonsity, from Alvogen) received FDA approval in 2019 and carries a list price roughly 20 to 30% below Forteo. Some GHC formularies have already moved generic teriparatide to a lower specialty subgroup or given it preferred status over brand Forteo. If your physician writes the prescription generically or for "teriparatide," GHC's pharmacy may substitute the lower-cost version automatically in states that allow generic substitution for biologics, reducing your out-of-pocket cost meaningfully.

With an approved PA, GHC specialty-tier copays on commercial plans generally range from $75 to $200 per 28-day fill (copay amounts vary by specific plan). Over 24 months, that translates to $1,800 to $4 to 800 in member cost-sharing, a significant but substantially lower amount than the list price.

The Lilly Cares Foundation (Eli Lilly manufactures Forteo) operates a patient assistance program for eligible uninsured or underinsured patients, available through the manufacturer's website. Income limits apply. This program does not apply to GHC-covered patients, but it may bridge gaps during a PA appeal if the physician can provide samples or a limited quantity while the appeal is pending.

How to Submit a Prior Authorization for Forteo Through GHC

Getting PA approved starts with your prescribing physician's office, not with you directly. Here is the sequence that tends to produce the fastest approvals:

Step 1: DXA documentation. Ensure that a recent DXA scan (within 24 months) is in the chart and that the T-score is documented at all measured sites. Reports should include the measured BMD value in g/cm2 alongside the T-score, because some PA reviewers want both.

Step 2: Fracture history. If a vertebral or hip fracture has occurred, include imaging reports. Vertebral fractures found incidentally on chest or spine X-rays ("asymptomatic vertebral fractures") still count as fragility fractures and significantly strengthen the clinical case.

Step 3: Prior bisphosphonate trial documentation. Pharmacy fill records, office notes, and any adverse-event documentation should be compiled. If the patient stopped alendronate because of esophagitis, a gastroenterologist's note or even the patient's own documented complaint in a progress note can constitute adequate evidence.

Step 4: FRAX score. Run the FRAX calculation (available free at sheffield.ac.uk/FRAX) and include it in the PA submission. A 10-year major osteoporotic fracture risk above 20% or hip fracture risk above 3% aligns with National Osteoporosis Foundation clinical guidelines.

Step 5: Specialist note (if required). If GHC's PA form requires specialist involvement, arrange an endocrinology or rheumatology consultation before submitting. Some plans accept a co-signed note rather than a formal referral visit.

Step 6: Submit via GHC's PA portal or fax. GHC provides a provider PA portal for electronic submission. Paper fax remains an option, but electronic submission typically generates a decision within 72 hours for non-urgent requests and 24 hours for urgent requests under CMS timelines for Medicare Advantage.

What Happens If GHC Denies the Prior Authorization?

A first-level PA denial is not the end of the road. GHC, like all ACA-compliant plans, must provide an internal appeal pathway and an external independent review option for medical necessity denials. The appeal process has specific timelines: for urgent care, a response is required within 72 hours; for standard pre-service appeals, within 30 days.

The strongest appeal letters include:

• Peer-reviewed literature supporting anabolic-first therapy in very high-risk patients. The VERO trial (N=1,360) compared teriparatide directly to risedronate in women with postmenopausal osteoporosis and two or more vertebral fractures. Teriparatide reduced new vertebral fractures by 56% relative to risedronate at 24 months (P<0.001), demonstrating superiority over a bisphosphonate rather than mere additive benefit.

• Guideline statements. The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline recommends anabolic therapy as initial treatment for patients with very high fracture risk, defined as T-score below -3.0, recent fracture within the past 12 months, or fractures on antiresorptive therapy.

• A letter of medical necessity from the prescribing physician that personalizes the clinical narrative rather than repeating generic language.

If the internal appeal fails, the patient can request an Independent Medical Review (IMR) through the Washington State Office of the Insurance Commissioner, which provides free, binding external review for Washington-based GHC plans.

Forteo Alternatives That GHC Typically Covers More Readily

If Forteo specifically is denied or cost-sharing is prohibitive, several other anabolic and antiresorptive options exist with different formulary positions on GHC plans.

Abaloparatide (Tymlos, Radius Health). Another PTH-related peptide anabolic agent, FDA-approved in 2017. The ACTIVE trial (N=2,463) showed abaloparatide reduced new vertebral fractures by 86% vs. placebo at 18 months and increased lumbar spine BMD by 9.2% vs. 4.8% for teriparatide. Some GHC formularies place Tymlos on a preferred specialty tier compared to Forteo, particularly if GHC has negotiated a better rebate from Radius Health. Ask the prescriber to check both drugs on the GHC formulary tool.

Romosozumab (Evenity, Amgen/UCB). A sclerostin inhibitor approved in 2019 for postmenopausal women at high fracture risk. Given as two subcutaneous injections monthly for 12 months. The FRAME trial (N=7,180) showed romosozumab reduced new vertebral fractures by 73% vs. placebo at 12 months. GHC plans subject romosozumab to similar specialty PA requirements, but some prefer it for patients with cardiovascular risk concerns around teriparatide (the teriparatide label carries warnings about hypercalcemia and orthostatic hypotension). Note: romosozumab carries its own boxed warning about myocardial infarction and stroke risk, so it is not appropriate for all patients.

Denosumab (Prolia, Amgen). A RANK-L inhibitor given as a 60 mg subcutaneous injection every 6 months. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fracture risk by 68% and hip fracture risk by 40% vs. placebo over 36 months. Denosumab is an antiresorptive rather than anabolic agent, but GHC plans often place it on a more accessible specialty tier than teriparatide, and some plans require denosumab as step therapy before approving anabolic agents.

Bisphosphonates (alendronate, risedronate, zoledronic acid). Generic alendronate is Tier 1 on virtually every GHC formulary at a cost of $4 to $10 per month. Intravenous zoledronic acid (Reclast) 5 mg once yearly is useful for patients who cannot tolerate oral bisphosphonates and is typically covered under the medical benefit rather than the pharmacy benefit, which changes the cost-sharing calculation entirely.

Special Situations: Medicare Advantage and Medicaid Through GHC

For GHC Medicare Advantage members, the Part D formulary rules add a layer of federal oversight. CMS requires that all Medicare Part D plans cover at least two drugs in each therapeutic category. For osteoporosis anabolic agents, that generally means both teriparatide and abaloparatide must be available on the formulary, although they can both be placed on a specialty tier with PA.

Medicare Advantage members also have access to the Extra Help (Low Income Subsidy) program if they meet income thresholds. Under Extra Help, specialty-tier copays are capped at roughly $11.20 per fill for 2024 (for full subsidy recipients), making a previously unaffordable drug financially accessible. The Social Security Administration Extra Help page provides eligibility criteria.

Washington State Medicaid (Apple Health) beneficiaries enrolled in GHC's Medicaid managed care product face a different formulary. Washington Apple Health covers teriparatide as a preferred drug with PA, under the Washington State Department of Social and Health Services Drug Criteria. Income-qualified patients should ask GHC's member services whether they qualify for cost-sharing reductions.

The Clinical Evidence Supporting Teriparatide Use

Understanding the evidence base helps patients and physicians build stronger PA and appeal arguments.

The key Fracture Prevention Trial (FPT, N=1,637) published in the New England Journal of Medicine demonstrated that teriparatide 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fractures by 53% vs. placebo over a median 21-month treatment period in postmenopausal women with prior vertebral fractures. Lumbar spine BMD increased by a mean of 9.7% from baseline. These results represent the highest level of evidence for any osteoporosis drug's anti-fracture efficacy in a high-risk population.

The FDA granted teriparatide approval for men with primary or hypogonadal osteoporosis as well, based on the trial data showing 13.5% mean increase in lumbar spine BMD at 12 months vs. 2.9% for placebo in male subjects.

For GHC members whose physicians need a single citation to anchor a PA appeal letter, the New England Journal of Medicine publication of the FPT is the most durable and widely recognized primary source. Insurance medical directors recognize NEJM publications as high-quality evidence, and citing trial name, journal, N-count, and effect size in the appeal letter signals clinical rigor.

Practical Cost-Reduction Strategies While Pursuing Coverage

Even with an approved PA, specialty-tier cost-sharing adds up. Several concrete steps can reduce out-of-pocket expense:

Use the generic teriparatide. If GHC's formulary lists generic teriparatide (Bonsity) at a lower tier or lower copay than brand Forteo, ask the physician to write the prescription as "teriparatide" without specifying the brand. Generic substitution rules in Washington allow this.

Lilly's 30-day free trial pen. Eli Lilly has historically offered a free first pen through participating pharmacies for commercially insured patients who are new to Forteo. Availability varies by year; the prescriber's office can verify current offers through the Forteo manufacturer portal.

Specialty pharmacy network. GHC may require dispensing through a network specialty pharmacy. Using an out-of-network specialty pharmacy can result in non-covered claims or higher cost-sharing. Confirm GHC's specialty pharmacy network before the first fill.

Copay accumulator programs. Some GHC commercial plans use copay accumulator adjusters, which means manufacturer copay cards do not count toward your deductible. Ask GHC's pharmacy benefit team directly whether manufacturer assistance counts toward your true out-of-pocket maximum.

If you are a GHC member with a T-score at or below -2.5 and documented vertebral fracture history, have your physician request PA with the FPT trial data, your FRAX score, and a specialist note included in the initial submission rather than saving those for the appeal.